background
present
studi
evalu
immunogen
toler
twodos
influenza
vaccin
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
compar
vaccineinduc
humor
respons
trigger
natur
infect
anoth
group
hsct
patient
method
adult
allogen
hsct
recipi
vaccin
two
dose
influenza
vaccin
separ
week
patient
proven
influenza
infect
includ
antibodi
respons
measur
hemagglutinationinhibit
assay
day
month
first
vaccin
inject
vaccin
patient
pandem
influenza
infect
patient
present
natur
infect
result
baselin
recipi
adjuv
vaccin
infect
patient
seroprotect
antibodi
titer
seroprotect
rate
observ
day
vaccin
differ
observ
natur
infect
respect
p
vaccin
patient
seroprotect
rate
increas
significantli
day
p
moreov
month
seroprotect
rate
vaccin
patient
similar
observ
infect
patient
evalu
least
day
infect
respect
p
multivari
analysi
immunosuppress
treatment
chronic
graftversushost
diseas
gvhd
longer
time
transplant
vaccinationinfect
associ
stronger
humor
respons
adjuv
vaccin
safe
low
rate
gvhd
worsen
conclus
hsct
recipi
two
dose
influenza
adjuv
vaccin
safe
induc
humor
respons
compar
trigger
natur
infect
patient
background
present
studi
evalu
immunogen
toler
twodos
influenza
vaccin
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
compar
vaccineinduc
humor
respons
trigger
natur
infect
anoth
group
hsct
patient
method
adult
allogen
hsct
recipi
vaccin
two
dose
influenza
vaccin
separ
week
patient
proven
influenza
infect
includ
antibodi
respons
measur
hemagglutinationinhibit
assay
day
month
first
vaccin
inject
vaccin
patient
pandem
influenza
infect
patient
present
natur
infect
result
baselin
recipi
adjuv
vaccin
infect
patient
seroprotect
antibodi
titer
seroprotect
rate
observ
day
vaccin
differ
observ
natur
infect
respect
p
vaccin
patient
seroprotect
rate
increas
significantli
day
p
moreov
month
seroprotect
rate
vaccin
patient
similar
observ
infect
patient
evalu
least
day
infect
respect
p
multivari
analysi
immunosuppress
treatment
chronic
graftversushost
diseas
gvhd
longer
time
transplant
vaccinationinfect
associ
stronger
humor
respons
adjuv
vaccin
safe
low
rate
gvhd
worsen
conclus
hsct
recipi
two
dose
influenza
adjuv
vaccin
safe
induc
humor
respons
compar
trigger
natur
infect
patient
elsevi
ltd
right
reserv
influenza
potenti
seriou
infect
hematopoiet
stem
cell
transplant
hsct
recipi
mortal
rate
around
report
untreat
patient
recent
data
suggest
improv
outcom
patient
treat
neuraminidas
inhibitor
larg
prospect
studi
allogen
hsct
recipi
influenza
infect
patient
low
respiratori
tract
diseas
requir
mechan
ventil
die
influenza
infect
complic
vaccin
inactiv
vaccin
main
prophylact
approach
influenza
infect
appear
less
effect
immunocompromis
patient
hsct
recipi
particularli
first
month
transplant
patient
graftversushost
diseas
gvhd
receiv
immunosuppress
treatment
popul
altern
modal
vaccin
evalu
use
second
dose
vaccin
allow
enhanc
humor
respons
studi
margin
effect
other
moreov
emerg
pandem
influenza
viru
prompt
use
oilinwateremuls
adjuv
enhanc
influenza
vaccin
immunogen
therefor
french
health
author
recommend
use
two
dose
adjuv
pandem
influenza
vaccin
allogen
hsct
recipi
prospect
studi
evalu
allogen
hsct
immunogen
safeti
two
dose
influenza
vaccin
safeti
assess
particularli
focus
potenti
risk
gvhd
worsen
adjuv
vaccin
potenti
could
trigger
immun
reaction
recipi
evalu
effect
vaccin
modal
compar
humor
respons
observ
adjuv
vaccin
observ
influenza
viru
infect
hsct
patient
includ
retrospect
primari
object
compar
humor
respons
observ
vaccin
dose
influenza
adjuv
vaccin
natur
infect
allogen
hsct
recipi
observ
studi
conduct
center
ais
de
greff
de
et
cellulair
vaccin
patient
prospect
includ
older
year
age
month
year
allogen
hematopoiet
stem
cell
transplant
main
exclus
criteria
relaps
hematolog
diseas
immunoglobulin
infus
last
month
season
influenza
vaccin
within
week
first
vaccin
dose
ongo
fever
infecti
diseas
allergi
egg
compon
vaccin
patient
receiv
two
intramuscular
inject
deltoid
muscl
monoval
influenza
vaccin
administ
day
apart
day
inclus
studi
day
first
vaccin
administr
influenzainfect
patient
older
year
follow
center
elig
studi
preepidem
frozen
serum
sampl
avail
postinfect
sera
sampl
least
day
infect
whenev
patient
came
followup
posttranspl
visit
day
sampl
posit
pcr
diagnosi
consid
day
patient
gave
oral
consent
particip
studi
requir
observ
studi
protocol
follow
declar
helsinki
french
law
fifti
nine
patient
receiv
inactiv
splitvirion
prepar
influenza
strain
contain
g
hemagglutinin
adjuv
pandemrix
gsk
uk
howev
patient
receiv
nonadjuv
vaccin
panenza
g
hemagglutinin
sanofipasteur
lyon
franc
accord
choic
physician
particularli
patient
activ
gvhd
vaccin
patient
record
occurr
sever
local
gener
reaction
unsolicit
advers
event
day
inject
clinic
biolog
data
potenti
onset
worsen
gvhd
also
collect
humor
respons
influenza
evalu
frozen
sera
use
hemagglutinationinhibit
hi
assay
modifi
kendal
et
al
briefli
treatment
receptor
destroy
enzym
twofold
dilut
serum
begin
test
hemagglutinin
unit
antigen
panenza
sanofipasteur
lyon
franc
human
rhesu
neg
red
blood
cell
titer
hemagglutinationinhibit
hi
antibodi
defin
reciproc
highest
serum
dilut
complet
inhibit
hemagglutin
vaccin
patient
sera
obtain
test
prior
vaccin
day
vaccin
inject
patient
sera
could
obtain
test
month
postimmun
infect
patient
avail
frozen
sera
sampl
onset
symptom
least
day
diagnosi
infect
test
immunogen
evalu
time
point
use
standard
hi
requir
use
european
regulatori
author
evalu
influenza
vaccin
emea
seroprotect
defin
antibodi
titer
seroconvers
prevaccinationinfect
titer
postvaccinationinfect
antibodi
titer
prevaccinationinfect
titer
least
fourfold
increas
vaccinationinfect
geometr
mean
antibodi
titer
gmt
also
calcul
endpoint
confid
interv
seroprotect
rate
percentag
patient
antibodi
titer
vaccinationinfect
seroconvers
rate
percentag
patient
seroconvert
vaccinationinfect
gmt
ratio
gmt
postvaccin
infectiongmt
infect
diagnos
nasopharyng
secret
realtim
revers
transcriptionpcr
assay
accord
nation
influenza
center
northernfr
protocol
institut
pasteur
pari
franc
center
diseas
control
protocol
cdc
myeloabl
condit
regimen
includ
either
high
dose
busulfan
dose
mgkg
oral
intraven
equival
high
dose
total
bodi
irradi
gy
fraction
dose
associ
cyclophosphamid
regimen
meet
criteria
classifi
reduc
intens
condit
ric
acut
chronic
gvhd
diagnos
clinic
andor
histolog
ground
base
standart
criteria
patient
receiv
prophylact
treatment
gvhd
time
studi
entri
treatment
consist
cyclosporin
case
patient
receiv
cur
treatment
gvhd
time
studi
entri
treatment
includ
corticosteroid
case
worsen
gvhd
defin
deterior
symptom
target
organ
alreadi
involv
appear
symptom
new
target
organ
seroprotect
seroconvers
rate
exact
confid
interv
ci
calcul
gmt
gmt
confid
interv
comput
take
expon
mean
lower
upper
limit
ci
logtransform
titer
seroprotect
seroconvers
rate
day
day
compar
use
mac
nemar
test
gmt
day
day
compar
use
student
ttest
pair
data
patient
characterist
immunogen
data
express
continu
variabl
compar
differ
group
use
kruskalw
global
test
subsequ
pairewis
multipl
comparison
use
bonferroniprotect
level
conoveriman
procedur
implement
xlstat
addinsoft
tm
comparison
characterist
patient
describ
qualit
variabl
use
fisher
exact
test
multivari
stepwis
logist
model
level
signific
entri
stay
use
adjust
covari
analysi
factor
associ
gmt
ratio
perform
use
univari
multivari
stepwis
linear
regress
model
logarithm
titer
ratio
use
threshold
analys
perform
use
sa
version
sa
institut
inc
cari
nc
usa
nineti
hsct
recipi
includ
studi
vaccin
adjuv
vaccin
receiv
first
dose
vaccin
novemb
februari
present
proven
influenza
infect
octob
march
eleven
patient
receiv
nonadjuv
vaccin
also
includ
studi
safeti
analysi
demograph
profil
clinic
characterist
studi
patient
describ
tabl
patient
vaccin
adjuv
vaccin
older
interv
transplant
inclus
studi
shorter
patient
vaccin
adjuv
vaccin
infect
patient
total
lymphocyt
count
inclus
higher
patient
vaccin
adjuv
vaccin
infect
patient
noteworthi
none
vaccin
patient
becam
influenzainfect
group
infect
patient
frequent
symptom
influenza
high
fever
patient
cough
nasal
discharg
myalgia
sixti
percent
patient
present
low
respiratori
tract
infect
acut
respiratori
distress
syndrom
coinfect
frequent
particular
respiratori
virus
coronaviru
n
rhinoviru
n
rsv
n
parainfluenza
viru
n
adenoviru
n
cmv
n
nineteen
patient
receiv
oseltamivir
nineteen
patient
recov
influenza
infect
one
patient
die
leukemia
relaps
still
excret
influenza
viru
despit
antivir
treatment
oseltamivir
zanamivir
among
infect
patient
avail
data
prior
influenza
vaccin
one
receiv
one
dose
pandem
vaccin
four
patient
receiv
second
vaccin
inject
due
occurr
advers
event
first
dose
adjuv
vaccin
one
nonadjuv
vaccin
p
local
gener
advers
event
report
vaccin
significantli
frequent
patient
receiv
adjuv
vaccin
compar
nonadjuv
one
vs
p
local
side
advers
event
vs
p
gener
advers
event
worsen
chronic
gvhd
occur
patient
adjuv
vaccin
nonadjuv
vaccin
p
baselin
seroprotect
rate
gmt
patient
vaccin
adjuv
vaccin
seroprotect
rate
increas
first
inject
second
one
p
likewis
seroconvers
rate
increas
p
gmt
p
subgroup
patient
specif
antibodi
titer
also
evalu
month
vaccin
fig
show
baselin
rise
antibodi
titer
serum
patient
four
time
point
thu
antibodi
titer
month
vaccin
lower
compar
howev
maintain
higher
valu
compar
baselin
humor
respons
influenza
measur
dose
adjuv
vaccin
patient
compar
observ
natur
infect
patient
tabl
baselin
differ
observ
seroprotect
rate
gmt
group
seroprotect
rate
vaccin
patient
infect
patient
p
similar
result
observ
seroconvers
rate
vs
p
gmt
vs
p
gmt
ratio
vs
p
vaccin
infect
patient
respect
sinc
rang
time
interv
molecular
diagnosi
influenza
infect
humor
respons
evalu
larg
day
median
valu
accur
analysi
perform
compar
humor
respons
subgroup
humor
respons
vaccin
n
compar
respons
obtain
infect
n
b
late
humor
respons
vaccin
n
compar
respons
obtain
infect
n
signific
differ
observ
three
paramet
earli
late
humor
respons
two
group
tabl
patient
vaccin
adjuv
vaccin
infect
includ
univari
multivari
analysi
order
identifi
factor
associ
antiinfluenza
humor
respons
set
result
univari
analysi
predict
factor
seroprotect
gmt
ratio
gvhd
graftversushost
diseas
cll
chronic
lymphocyt
leukemia
pvalu
global
comparison
three
group
patient
differ
signific
adjuv
vaccin
nonadjuv
vaccin
p
influenza
infect
patient
p
differ
signific
adjuv
vaccin
influenza
infect
patient
p
differ
signific
adjuv
vaccin
influenza
infect
patient
p
shown
tabl
seroprotect
rate
posit
associ
longer
delay
transplant
inclus
lymphocyt
count
myeloabl
condit
regimen
neg
associ
chronic
gvhd
treatment
immunosuppress
drug
inclus
chronic
gvhd
treatment
immunosuppress
drug
inclus
associ
lower
gmt
ratio
interestingli
type
immun
infect
vaccin
includ
analysi
variabl
associ
influenza
humor
respons
multivari
analysi
treatment
immunosuppress
drug
inclus
associ
lower
seroprotect
rate
odd
ratio
ci
p
moreov
chronic
gvhd
short
delay
transplant
inclus
day
associ
lower
gmt
ratio
tabl
seroprotect
rate
defin
percentag
patient
hi
titer
seroconvers
rate
percentag
patient
prevaccinationinfect
hi
titer
postvaccinationinfect
titer
show
signific
increas
antibodi
titer
defin
prevaccinationinfect
titer
least
fourfold
increas
postvaccinationinfect
titer
geometr
mean
titer
ratio
seroconvers
factor
geometr
mean
withinsubject
ratio
postvaccinationinfect
reciproc
hi
titer
day
reciproc
hi
titer
fisher
exact
test
except
kruskalw
comparison
late
humor
respons
administr
adjuv
vaccin
dose
natur
infect
first
studi
allogen
hsct
recipi
compar
immunogen
induc
influenza
vaccin
natur
infect
show
vaccin
two
dose
adjuv
influenza
vaccin
elicit
specif
humor
respons
compar
achiev
infect
inde
two
three
emea
serolog
criteria
assess
vaccin
immunogen
immunocompet
individu
seroconvers
rate
gmt
ratio
fulfil
third
one
nearli
reach
seroprotect
rate
instead
requir
studi
allogen
hsct
recipi
show
similar
respons
use
vaccin
regimen
higher
respons
also
report
nevertheless
studi
includ
patient
differ
clinic
characterist
particular
longer
period
time
transplant
vaccin
present
studi
highli
suggest
use
second
dose
vaccin
hsct
patient
begin
influenza
pandemia
expect
two
dose
adjuv
vaccin
would
necessari
induc
substanti
humor
respons
even
immunocompet
subject
singl
inject
subsequ
shown
suffici
contrast
differ
type
immunocompromis
patient
sever
studi
report
second
inject
necessari
achiev
antibodi
titer
compar
obtain
control
subject
one
inject
present
studi
hsct
recipi
plan
receiv
dose
vaccin
recommend
french
guidelin
recent
guidelin
ecil
signific
increas
specif
antibodi
titer
first
second
administr
adjuv
vaccin
highli
suggest
interest
second
dose
vaccin
howev
design
studi
total
exclud
delay
respons
first
vaccin
furthermor
show
respons
durabl
sinc
patient
remain
seroprotect
month
note
longterm
humor
immun
induc
influenza
vaccin
hsct
recipi
previous
evalu
littl
inform
antibodi
dynam
induc
natur
influenza
infect
human
studi
compar
humor
immun
respons
induc
influenza
vaccin
natur
infect
conduct
immunocompet
subject
herein
show
seroprotect
rate
well
gmt
antibodi
day
even
statist
differ
infect
vaccin
patient
suggest
regimen
two
dose
adjuv
vaccin
effici
natur
infect
induc
specif
humor
respons
hsct
patient
moreov
tendenc
although
signific
toward
higher
gmt
long
term
vaccin
patient
previous
report
nonhsct
recipi
knowledg
data
first
show
humor
respons
vaccin
least
good
respons
induc
natur
infect
hsct
recipi
argu
use
dose
adjuv
vaccin
patient
factor
influenc
influenza
humor
respons
hsct
previous
report
studi
conduct
evalu
vaccin
respons
analysi
factor
influenc
humor
respons
influenza
consid
patient
singl
group
vaccin
infect
variabl
factor
multivari
analysi
data
show
humor
respons
independ
type
influenza
immun
ie
natur
infect
adjuv
vaccin
depend
sever
paramet
time
interv
transplant
vaccinationinfect
treatment
immunosuppress
drug
presenc
chronic
gvhd
inclus
result
must
consid
establish
new
schedul
vaccin
immunocompromis
patient
previous
report
total
lymphocyt
count
associ
seroprotect
rate
univari
analysi
howev
associ
remain
multivari
analysi
explain
lymphocyt
count
highli
depend
administr
immunosuppress
treatment
use
nonadjuv
vaccin
group
patient
allow
compar
intens
frequenc
advers
event
two
type
vaccin
despit
poor
number
patient
vaccin
non
adjuv
vaccin
observ
expect
advers
event
moder
intens
frequent
adjuv
compar
nonadjuv
vaccin
lower
previous
report
proport
patient
receiv
second
dose
due
advers
event
compar
two
group
observ
rate
chronic
gvhd
worsen
remain
low
group
main
limit
studi
small
number
infect
patient
retrospect
inclus
led
larg
time
interv
blood
sampl
infect
howev
consid
hsct
recipi
proven
infect
relev
control
group
evalu
new
modal
vaccin
despit
heterogen
small
number
patient
includ
group
conclus
studi
vaccin
two
dose
influenza
adjuv
vaccin
safe
allogen
hsct
recipi
allow
gener
humor
respons
compar
trigger
natur
infect
humor
respons
observ
vaccin
immunosuppress
popul
reach
emea
criteria
evalu
influenza
vaccin
healthi
subject
lack
seroprotect
patient
natur
infect
vaccin
like
explain
poor
posttranspl
immun
recoveri
nd
ak
princip
investig
take
primari
respons
paper
ba
particip
design
studi
nd
bl
job
pa
mtr
pr
recruit
patient
ak
nlc
jlg
ba
perform
laboratori
work
studi
perform
statist
analysi
nd
ak
pr
nlc
wrote
paper
